Incremental effects of SGLT2 inhibitors, GLP-1 receptor agonists, and pioglitazone in type 2 diabetes and MASLD across Asian study settings: a systematic review and meta-analysis

More on GLP-1 receptor agonists

• SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

  Diabetes & Vascular Disease Research · 4 Oct 2026

• SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes

  Clinical Journal of the American Society of Nephrology · 4 Oct 2026

• Retatrutide reduces bodyweight in obesity and type 2 diabetes

  Lancet · 4 Oct 2026

• Survodutide reduces weight in adults with diabetes and obesity

  The New England Journal of Medicine · 4 Oct 2026